A carregar...
Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma
OBJECTIVES: The incidence of metastatic renal cell cancer (mRCC) is rising. To date, Interleukin-2 (IL-2) is the only treatment offering a complete response rate for mRCC. We wish to test the hypothesis that the combination of restricted availability and expense associated with IL-2 administration r...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2864345/ https://ncbi.nlm.nih.gov/pubmed/19070518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2008.09.022 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|